News & Updates

Show Multimedia Only

COVID-19 may trigger hair, nail disorders

21 Nov 2022

Hair and nail disorders may occur following contraction of COVID-19 infection, with the development of the dermatological conditions related to a history of severe infection, a study has found.

21 Nov 2022

Oral ritlecitinib shows promise against nonsegmental vitiligo

17 Nov 2022

The use of ritlecitinib, an oral JAK3/TEC inhibitor, appears effective for the treatment of nonsegmental vitiligo (NSV) and is well-tolerated for over 48 weeks of follow-up, reports a recent study.

17 Nov 2022

Lichen sclerosus tied to sexual dysfunction in women

16 Nov 2022

Sexual dysfunction commonly occurs in many women with lichen sclerosus (LS), reveals a study, noting that further research is warranted, particularly that which includes biopsy-proven LS and validated tools on sexual function.

16 Nov 2022

Cinnamic aldehyde, alcohol cause reactions in fragrance allergy

12 Nov 2022

A prospective study has revealed that cinnamic aldehyde and cinnamic alcohol are the most common allergens that cause immediate and delayed reactions among patients with allergic contact dermatitis to fragrance. In addition, reactions to benzyl alcohol, sorbic acid, and coumarin are usually seen in immediate patch tests.

12 Nov 2022

Clustering predicts relapse in eosinophilic fasciitis patients

11 Nov 2022

Patients with eosinophilic fasciitis (EF) can be categorized into homogenous clusters that help predict relapse and sequelae, together with fibrosis and eosinophilia, suggests a study.

11 Nov 2022

First-line pembrolizumab feasible for BRAF V600–mutant melanoma

10 Nov 2022

A recent study recommends the use of pembrolizumab over BRAF/mitogen-activated protein kinase inhibitors, such as dabrafenib/trametinib, as first-line treatment in patients with advanced BRAF V600‒mutant advanced malignant melanoma.

10 Nov 2022

Atezolizumab–bevacizumab combo shows therapeutic potential in advanced mucosal melanoma

04 Nov 2022

The combination of atezolizumab plus bevacizumab demonstrates promising antitumour activity in patients with advanced mucosal melanoma while having a manageable safety profile, according to the results of a phase II study.

04 Nov 2022

Phase II data shows treatment potential of litifilimab for CLE

27 Oct 2022 by

In part B* of the two-part 16-week LILAC study, the anti-BDCA2** antibody litifilimab reduced skin disease activity in individuals with cutaneous lupus erythematosus (CLE).

27 Oct 2022